MBX BIOSCIENCES ($MBX) posted quarterly earnings results on Thursday, November 6th. The company reported earnings of -$0.63 per share, beating estimates of -$0.69 by $0.06. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $MBX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
MBX BIOSCIENCES Insider Trading Activity
MBX BIOSCIENCES insiders have traded $MBX stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $MBX stock by insiders over the last 6 months:
- PATRICK J HERON purchased 666,666 shares for an estimated $11,999,988
- P. KENT HAWRYLUK (President & CEO) purchased 20,000 shares for an estimated $272,790
- STEVEN L. HOERTER purchased 20,000 shares for an estimated $264,984
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
MBX BIOSCIENCES Hedge Fund Activity
We have seen 2 institutional investors add shares of MBX BIOSCIENCES stock to their portfolio, and 2 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH added 28,461 shares (+inf%) to their portfolio in Q3 2025, for an estimated $498,067
- BANK OF NEW YORK MELLON CORP added 9,703 shares (+25.5%) to their portfolio in Q3 2025, for an estimated $169,802
- KOA WEALTH MANAGEMENT, LLC removed 5,039 shares (-15.9%) from their portfolio in Q3 2025, for an estimated $88,182
- ALPS ADVISORS INC removed 1,208 shares (-6.7%) from their portfolio in Q3 2025, for an estimated $21,140
- PHYSICIAN WEALTH ADVISORS, INC. added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
- NEW YORK STATE COMMON RETIREMENT FUND added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
- NISA INVESTMENT ADVISORS, LLC added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
MBX BIOSCIENCES Analyst Ratings
Wall Street analysts have issued reports on $MBX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 11/04/2025
- Mizuho issued a "Outperform" rating on 09/24/2025
- Oppenheimer issued a "Outperform" rating on 09/23/2025
- Jefferies issued a "Buy" rating on 08/15/2025
To track analyst ratings and price targets for MBX BIOSCIENCES, check out Quiver Quantitative's $MBX forecast page.
MBX BIOSCIENCES Price Targets
Multiple analysts have issued price targets for $MBX recently. We have seen 5 analysts offer price targets for $MBX in the last 6 months, with a median target of $56.0.
Here are some recent targets:
- Srikripa Devarakonda from Truist Securities set a target price of $50.0 on 10/15/2025
- Uy Ear from Mizuho set a target price of $56.0 on 09/24/2025
- Seamus Fernandez from Guggenheim set a target price of $84.0 on 09/23/2025
- Trevor Allred from Oppenheimer set a target price of $80.0 on 09/23/2025
- Roger Song from Jefferies set a target price of $36.0 on 08/15/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
